Simulations Plus Inc. (NASDAQ:SLP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies. “
Simulations Plus (NASDAQ:SLP) opened at 8.48 on Wednesday. The company’s 50 day moving average price is $8.64 and its 200-day moving average price is $8.23. Simulations Plus has a one year low of $6.74 and a one year high of $11.89. The company has a market cap of $144.59 million, a P/E ratio of 31.41 and a beta of -0.26.
Simulations Plus (NASDAQ:SLP) last issued its earnings results on Thursday, July 14th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by $0.01. The business had revenue of $6.01 million for the quarter. Simulations Plus had a net margin of 23.58% and a return on equity of 22.89%. On average, analysts forecast that Simulations Plus will post $0.28 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its stake in Simulations Plus by 6.0% in the second quarter. Dimensional Fund Advisors LP now owns 339,427 shares of the company’s stock worth $2,566,000 after buying an additional 19,087 shares during the last quarter. Crawford Investment Counsel Inc. increased its stake in Simulations Plus by 36.3% in the second quarter. Crawford Investment Counsel Inc. now owns 280,178 shares of the company’s stock worth $2,118,000 after buying an additional 74,574 shares during the last quarter. Skylands Capital LLC increased its stake in Simulations Plus by 103.8% in the second quarter. Skylands Capital LLC now owns 248,834 shares of the company’s stock worth $1,881,000 after buying an additional 126,734 shares during the last quarter. Ancora Advisors LLC increased its stake in Simulations Plus by 108.1% in the second quarter. Ancora Advisors LLC now owns 191,472 shares of the company’s stock worth $1,448,000 after buying an additional 99,453 shares during the last quarter. Finally, Mckinley Capital Management LLC Delaware purchased a new stake in Simulations Plus during the first quarter worth about $1,325,000. 25.30% of the stock is currently owned by institutional investors.
Simulations Plus Company Profile
Simulations Plus, Inc (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Simulations Plus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.